Evidence map›Paper›PMID 20697629›Full record

ReviewChemical Society reviews2010

Designing multifunctional quantum dots for bioimaging, detection, and drug delivery.

Pavel Zrazhevskiy, Mark Sena, Xiaohu Gao

Abstract readReview
In one paragraph

Review in Chemical Society reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Science and technology of advanced materials · 2025
    Article
  16. Review
  17. Emerging Nanomedicine Approaches in Targeted Lung Cancer Treatment.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Review
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pavel ZrazhevskiyDepartment of Bioengineering, University of Washington, 3720 15th Avenue NE, Seattle, WA 98195, USA.
Mark Sena
Xiaohu Gao

Funding

Sensitive and multiplexed analysis of cancer biomarkers with QD barcodesR01CA131797 · NCI · UNIVERSITY OF WASHINGTON · PI GAO, XIAOHU · 2008 to 2012
$1.6M
Targeted and traceable delivery of siRNA with nanoparticle-amphipolR01CA140295 · NCI · UNIVERSITY OF WASHINGTON · PI GAO, XIAOHU · 2009 to 2010
$647k
NCI NIH HHS R01 CA131797NCI NIH HHS R01CA131797NCI NIH HHS R01 CA140295NCI NIH HHS R01CA140295
6 · The paper itself

Abstract

The emerging field of bionanotechnology aims at revolutionizing biomedical research and clinical practice via introduction of nanoparticle-based tools, expanding capabilities of existing investigative, diagnostic, and therapeutic techniques as well as creating novel instruments and approaches for addressing challenges faced by medicine. Quantum dots (QDs), semiconductor nanoparticles with unique photo-physical properties, have become one of the dominant classes of imaging probes as well as universal platforms for engineering of multifunctional nanodevices. Possessing versatile surface chemistry and superior optical features, QDs have found initial use in a variety of in vitro and in vivo applications. However, careful engineering of QD probes guided by application-specific design criteria is becoming increasingly important for successful transition of this technology from proof-of-concept studies towards real-life clinical applications. This review outlines the major design principles and criteria, from general ones to application-specific, governing the engineering of novel QD probes satisfying the increasing demands and requirements of nanomedicine and discusses the future directions of QD-focused bionanotechnology research (critical review, 201 references).

Indexed as

BiotechnologyDrug Delivery SystemsNanotechnologyQuantum Dots

Identifiers

PMID20697629
PMCPMC3212036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.